ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > hope

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Nov 15, 2020 3:51pm

128 Views

Post# 31903594

RE:RE:RE:RE:RE:RE:hope

Exactly.....that's whooping I was ho08ng someone had access to the stat publication..what we could see that the advisory committee actually mentioned that they are only dealing with the Biogen submission...they can't comment or won't comment on the validity of the amyloid science. PMN just needs one large company to decide that the amyloid approach is worth it...the advisory board didn't say it wasn't working..they just said itwasnt working good enough for their liking...

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects